TXMD trading volume has lost -1465907 shares compared to readings over the past three months as it recently exchanged 1634093 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 3100000 shares, and this is 0.53 times the normal volume. A look at its technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 54.99 point.
TherapeuticsMD, Inc. (NASDAQ:TXMD) climbed by 13.28% over the past three months which led to its overall six-month increase to stand at 1.93%. The equity price sank -8.16% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a 5.38% gain over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -0.94% and is now up by 38.85% since start of this year.
The shares of TherapeuticsMD, Inc. dropped by -30.94% or -$2.37 from its last recorded high of $7.66 which it attained on June 08 to close at $5.29 per share. Over the past 52 weeks, the shares of TherapeuticsMD, Inc. has been trading as low as $3.51 before witnessing a massive surge by 50.71% or $1.78. This price movement has led to the TXMD stock receiving more attention and has become one to watch out for. It jumped by 1.15% on Monday and this got the market excited. The stock’s beta now stands at 2.07 and when compared to its 200-day moving average and its 50-day moving average, TXMD price stands -6.24% below and 13.47% above respectively. Its average daily volatility for this week is 5.19% which is more than the 4.84% recorded over the past month.
Experts from research firms are bullish about the near-term performance of TherapeuticsMD, Inc. (TXMD) with most of them predicting a $16 price target on a short-term (12 months) basis. The average price target by the analysts will see a 202.46% rise in the stock and would lead to TXMD’s market cap to surge to $3.95B. The stock has been rated an average 0, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 8 analysts that track TherapeuticsMD, Inc. (NASDAQ:TXMD) and find out that 1 of them rated it as a Hold. 7 of the 7 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.
Analysts have predicted a price target for Sunstone Hotel Investors, Inc. (SHO) for 1 year and it stands at an average $14.54/share. This means that it would likely increase by 2.32% from its current position. The current price of the stock has been moving between $14.17 and $14.4. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $12. On the other hand, one analyst is super bullish about the price, setting a target as high as $16.
The SHO stock Stochastic Oscillator (%D) is at 80.52%, which means that it is currently overbought and its prices could dip very soon. The shares P/S ratio stands at 2.82 which compares to the 8.86 recorded by the industry or the 10.37 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 30.23, which is higher than the 17.56 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 34.5% over the past five years.
Analysts view Sunstone Hotel Investors, Inc. (NYSE:SHO) as a Sell, with 3.2 consensus rating. Reuters surveyed 13 analysts that follow SHO and found that 10 of those analysts rated the stock as a Hold. The remaining 3 were divided, with 0 analyst rating it as a Buy or a Strong Buy while 3 analysts advised investors to desist from buying Sunstone Hotel Investors, Inc. (SHO) shares or sell it if they already own it.
This post was originally published on *this site*